Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.69 |
| ▸ | HPGDS | O60760 | 2/20 | 0.63 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246554 | 0.96 | LDHA (0.73) | LDHAHPGDSBAZ2BMKNK1MKNK2 | |
| SCHEMBL29586559 | 0.96 | LDHA (0.73) | LDHAHPGDSBAZ2BMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL5010814 | 0.95 | LDHA (0.71) | LDHAHPGDSBAZ2BMKNK1MKNK2 | |
| SCHEMBL1758435 | 0.86 | PARP10 (0.63) | LDHAHPGDSBAZ2BFYNCYP11B1 | |
| SCHEMBL1758318 | 0.83 | HPGDS (0.56) | LDHAHPGDSBAZ2BMKNK1MKNK2 | |
| SCHEMBL12647420 | 0.83 | HPGDS (0.55) | LDHAHPGDSBAZ2BMKNK1MKNK2 | |
| SCHEMBL5658059 | 0.83 | RXFP1 (0.73) | LDHAHPGDSBAZ2BMKNK1MKNK2 | |
| SCHEMBL11009430 | 0.83 | MAP4K4 (0.60) | LDHAHPGDSMKNK1MKNK2NPC1 | |
| SCHEMBL505455 | 0.82 | LDHA (1.00) | LDHAHPGDSBAZ2BNPC1SMN1; SMN2 | |
| SCHEMBL27584594 | 0.82 | LDHA (0.79) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | claimed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | claimed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | claimed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | claimed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | claimed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | claimed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | claimed |
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | disclosed |
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | disclosed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | disclosed |
| US-7105549-B2 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-09-12 | — | — | US | disclosed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | disclosed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | disclosed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | LDHA 162/4885HPGDS 3962/4885BAZ2B 3456/4885 |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | CACNA1S, CACNA1E, CACNA1C | LDHA 194/4885HPGDS 4009/4885BAZ2B 3372/4885 |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1D | LDHA 164/4885HPGDS 3747/4885BAZ2B 3800/4885 |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | LDHA 162/4885HPGDS 3962/4885BAZ2B 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.